Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Primary diagnose HNSCC carcinoma patients eligible for curative surgery will be proposed the
addition of 2 or 3 neoadjuvant cetuximab infusions. The main objective is to reduce to a
minimal delay the time elapsing between last infusion and surgery.
Iterative biomarkers will be taken at 6 time points permitting to investigate expression gen
profile and protein mutation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators:
Merck Serono International SA Merck Sharp & Dohme Corp.